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Summary The concept of clopidogrel resistance emerged several years ago. Since then, many
studies have been performed to elucidate the mechanisms and potential clinical impact of this
biological ﬁnding. These studies identiﬁed complex mechanisms, including drug—drug interac-
tions, genetic polymorphisms and clinical factors, and showed consistently the clinical relevance
of the variability of clopidogrel response, with higher ischaemic risk in low-responders or non-
responders, and higher bleeding risk in hyper-responders. Several strategies for overcoming
clopidogrel resistance have been evaluated in small clinical studies, but the beneﬁt of tailored
antiplatelet therapy has yet to be validated in large randomized trials, which are currently
ongoing. Upcoming antiplatelet drugs that are more potent will change the ﬁeld of antiplatelet
therapy in acute coronary syndromes. The future of antiplatelet therapy sounds more complex,
with different drugs, and tailored therapy based on platelet tests and/or genetic testing, but
it will lead us to propose a more individualized therapy, which hopefully will improve patient
outcome.
© 2010 Elsevier Masson SAS. All rights reserved.MOTS CLÉS
Traitement
antiplaquettaire ;
Résistance au
clopidogrel ;
Résumé Le concept de résistance au clopidogrel est apparu depuis quelques années. Depuis,
de nombreuses études ont été menées pour élucider les mécanismes ainsi que les conséquen-
ces cliniques de cette entité biologique. Ces études ont démontré un mécanisme complexe,
incluant des interactions médicamenteuses, ainsi que des facteurs génétiques et cliniques,
et ont montré de fac¸on constante l’impact clinique de cette variabilité de réponse. De nom-
breuses stratégies ont été proposées pour s’affranchir de cette résistance, mais le bénéﬁce
Abbreviations: CYP, cytochrome P450; HPI, high on-treatment platelet inhibition; HPR, high on-treatment platelet reactivity; LTA,
light transmission aggregometry; PRI, platelet reactivity index; VASP, vasoactive stimulated phosphoprotein.
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d’un traitement individualisé sur les tests plaquettaires doit encore être démontré dans de
larges essais cliniques, actuellement en cours. Les nouvelles molécules antiplaquettaires, plus
puissantes, vont bien sûr modiﬁer le traitement antiplaquettaire des syndromes coronariens
aigus. Le traitement antiplaquettaire du futur apparaît alors plus complexe avec différentes
molécules, voire un traitement individualisé sur les tests plaquettaires et/ou génétiques, mais
cela nous amènera à proposer un traitement plus personnalisé à chaque patient, ce qui ne peut
qu’améliorer leur pronostic.
© 2010 Elsevier Masson SAS. Tous droits réservés.
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ehe concept of clopidogrel resistance or non-response has
merged from numerous trials over the past decade. To fully
nderstand this concept, its implication for patients and the
olutions that are being developed and evaluated, cardi-
logists should increase the ﬁeld of their knowledge and
ake an interest in the pharmacological properties of the
econd-most-sold drug in the world.
Firstly, clopidogrel, as part of the thienopyridine class, is
prodrug. It undergoes a series of transformations to yield
n active metabolite, which is the real P2Y12 inhibitor. After
ts absorption, approximately 85% of the clopidogrel dose is
ydrolyzed by esterases to an inactive metabolite and can-
ot be converted into the active metabolite. The remaining
5% undergoes a two-step oxidation by a series of hepatic
ytochrome P450 s (CYPs) to generate the active metabolite,
hich is able to bond irreversibly with the P2Y12 receptor
nd therefore inhibit platelet aggregation.
Among the hepatic enzymes that contribute to this
etabolic process, a key enzyme —CYP2C19— has been
hown to have many isoforms, which produces large vari-
bility in its catalytic activity. This variability translates
nto different rates of conversion of clopidogrel into its
ctive compound, which can attenuate (2C19*2, 2C19*3) or
nhance (2C19*17) the pharmacodynamic effect of the drug
1,2]. Recently, the loss-of-function variant 2C19*2, which
s present in about 30% of Caucasians and up to 60% of the
sian population, has been associated with decreased acti-
ation of clopidogrel, resulting in a reduced antiplatelet
ffect [3,4]. More importantly, the ‘‘genetic resistance’’
nduced by the carriage of at least one CYP2C19*2 allele
ranslates into a signiﬁcantly increased risk of recurrent car-
iovascular events, including a dramatic threefold increase
n stent thrombosis in patients receiving clopidogrel therapy
5—7]. To make it even simpler, several other mechanisms
ave been identiﬁed that induce a decreased response,
ncluding drug-to-drug interactions through the same hep-
tic cytochrome (P450), as described recently with proton
ump inhibitors [8,9], and clinical factors such as diabetes
nd being overweight [10].
These recent ﬁndings clearly support the need for
latelet function tests, to identify non-responder candi-
ates for treatment adaptation (under the hypothesis that
ailored therapy will lower recurrent events), and more
otent antiplatelet agents to overcome the non-response
o clopidogrel, such as prasugrel, which is less sensitive to
ytochrome polymorphism, or ticagrelor, which inhibits the
2Y12 receptor directly and avoids hepatic metabolization.
Several methods have been used to assess clopidogrel-
nduced antiplatelet effects but only three tests have been
t
c
atudied extensively in the clinical research setting. Light
ransmission aggregometry (LTA) is still considered as the
old standard method and has been used largely in prospec-
ive studies, to evaluate response to clopidogrel and predict
ardiovascular events. Flow cytometry assessment of the
hosphorylation of Vasoactive Stimulated Phosphoprotein
VASP), an intracellular actin protein, is also well corre-
ated with inhibition induced by clopidogrel, and has the
dvantage of being very speciﬁc for the P2Y12 recep-
or. Unfortunately, these two tests require equipment and
echnicians, and are both time- and cost-consuming. The
erifyNow system (Accumetrics, Inc., San Diego, CA. USA)
s a fully automated, point-of-care test, which is easy to
se and can measure platelet response to clopidogrel in
few minutes. This assay has been well correlated with
TA [11—13] and VASP Platelet Reactivity Index (PRI), and
s probably the optimal assay for platelet measurement
n a clinical setting because of its potential availability
n catheterization laboratories. Nevertheless, the utility of
uch a test remains to be proven in large, randomized, clin-
cal studies.
The clinical relevance of the concept of clopidogrel
esistance or non-response has been investigated broadly.
everal clinical studies, using the above-mentioned platelet
unction tests, have demonstrated that patients with High
n-treatment Platelet Reactivity (HPR) or clopidogrel resis-
ance have an increased risk of ischaemic events, including
tent thrombosis [14,15].
Mateztky et al. were the ﬁrst to demonstrate, in a
mall population of patients with ST-elevation myocardial
nfarction, that patients in the ﬁrst quartile of response to
lopidogrel (considered as non-responders to clopidogrel)
ere at high risk of having a recurrent cardiovascular event
t 6 months [16]. In this study, clopidogrel response was
eﬁned as the variation of platelet inhibition from a baseline
alue. This method, which evaluated the relative response
o clopidogrel, is not always suitable for daily clinical prac-
ice because baseline samples are not often available due
o chronic clopidogrel therapy or night admission. Moreover,
tudies have shown good correlation between non-response
o clopidogrel (small difference between pre-treatment and
ost-treatment values) and HPR, which only necessitates
ne post-treatment platelet measurement. Therefore HPR
as considered as a good estimate of thrombotic risk and
nables high-risk patients with non-response to clopidogrel
o be deﬁned [17].
The recent POPULAR study is the largest and most
omplete study conducted so far, evaluating the potential
dditive predictive value of several platelet tests in the
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assessment of risk or recurrent ischaemic events [18]. The
ﬁrst conclusion of this study is that there is only a small
additive value to platelet function tests in ischaemic risk
assessment compared with clinical and angiographic risk
models. Nevertheless, the platelet function test remains
useful as an independent risk marker for clinicians. The
second conclusion is that only some tests were able to
predict recurrent events (LTA, VerifyNow, Platelet Works
[Helena Laboratories, Beaumont, TX, USA]) while others
were not (PFA-100 [Siemens Healthcare Diagnostics, Deer-
ﬁeld, IL, USA]). Unfortunately VASP PRI was not evaluated
in this head-to-head comparison study, but should still be
considered as an efﬁcient test on the basis of other clinical
studies [19]. The most difﬁcult problem remaining after all
these studies is that there is still no consensus on the def-
inition of clopidogrel resistance or non-response [20]. The
threshold for deﬁning non-responders or patients with HPR
is still unknown and will be difﬁcult to address, as the level
of platelet response varies from one day to the next and
from acute situations to stable patients.
Looking at the other side of platelet response, clini-
cians interested in bleeding complications have noticed that
some patients can be hyper-responders, and have published
data supporting the association between High on-treatment
Platelet Inhibition (HPI) and bleeding complications [2,21].
Therefore, the concept of an ‘‘optimal’’ therapeutic range
of platelet inhibition was born, and might help to reduce
both ischaemic and bleeding complications in coronary
patients treated with clopidogrel.
Over the past decade, different strategies have been
evaluated to overcome HPR and clopidogrel resistance, with
the ultimate goal of obtaining an optimal antiplatelet ther-
apy regimen that is both highly efﬁcient and safe. As a
result of the development of new antiplatelet agents and
the outcomes of recent mechanistic studies and clinical tri-
als, we now know that there is still a lot of work to do
to get close to the perfect antiplatelet regimen, and that
‘‘one does not ﬁt all’’ in terms of antiplatelet therapy.
The prescription of dual antiplatelet therapy, with aspirin
(75—325mg) associated with clopidogrel (300mg loading
dose/75mg maintenance dose) for all coronary patients can
be considered as obsolete.
The ﬁrst solution to avoid variability of clopidogrel
response with conventional doses (300mg/75mg) is to
increase doses in every patient, to provide a higher degree of
platelet inhibition and a lower rate of HPR or non-response
[11,22]. In terms of evidence-based medicine and clinical
efﬁciency, the results of the randomized CURRENT-OASIS-7
trial now support an increase in the loading dose of clopi-
dogrel to 600mg and in the maintenance dose to 150mg
in acute coronary syndrome patients treated with percuta-
neous coronary intervention [23,24]. However, the absence
of beneﬁt in patients treated medically and the fear of
bleeding complications with high doses have not yet con-
vinced all cardiologists to change their habits.
The second solution is to provide a tailored therapy
based on a platelet function test. Small-randomized studies
already support the beneﬁt of tailored therapy in the setting
of percutaneous coronary intervention in patients with HPR,
with either repeated loading doses of clopidogrel 600mg
[25] or the use of glycoprotein IIb/IIIa antagonists [26,27].
However, the beneﬁt of individualized therapy based on a
c
t
i
a
t351
latelet function test will have to be conﬁrmed in large,
linical trials, and the VerifyNow system has been cho-
en to demonstrate the superiority of tailored therapy in
atients receiving a drug-eluting stent in the ongoing ARC-
IC (NCT00827411) and GRAVITAS (NCT006645918) studies.
ecent advances in the pharmacogenetics of clopidogrel and
he development of fast genetic testing (< 2 h) provide the
ealistic prospect of a personalized choice of tailored dose
djustment for each individual patient, based on genetic
nd/or platelet function testing [28].
The third solution is to use new drugs, which are more
otent and have less interindividual variability. Platelet
nhibition can be obtained by inhibiting several platelet
eceptors but the P2Y12 receptor has proven to be a key
arget in the prevention of complications; hence, several
ew drugs have been developed to target the P2Y12 adeno-
ine diphosphate receptor and obtain a high level of platelet
nhibition. Some of these drugs are new thienopyridines
prasugrel and elinogrel) and some are non-thienopyridine
nhibitors (ticagrelor and cangrelor). Faster onset of action
ill be provided by intravenous agents that do not require
bsorption or metabolization, such as cangrelor and elino-
rel, but fast-acting oral drugs, such as ticagrelor and
rasugrel, also provide faster speed and a higher level of
nhibition than clopidogrel, even when using high doses (up
o 900mg) [29,30].
Two of these new drugs will soon be obtainable —
rasugrel, which is already available, and ticagrelor, which
s undergoing Food and Drug Administration approval—
s they demonstrated better efﬁcacy in two large, random-
zed trials (TRITON-TIMI 38 and PLATO) compared with classic
ual antiplatelet therapy based on aspirin and clopidogrel
31,32]. Both drugs produced similar relative reductions
19% and 16%, respectively) in the primary ischaemic end-
oint (death, myocardial infarction and stroke) in an acute
oronary syndrome population, and even greater reductions
n subgroups, such as in patients with ST-segment eleva-
ion myocardial infarction, those treated with percutaneous
oronary intervention and diabetic patients, where the risk
roﬁle is higher. Additionally, ticagrelor was the third drug,
fter aspirin in the ISIS-2 trial and clopidogrel in the COM-
IT trial, to demonstrate a signiﬁcant absolute reduction in
erms of mortality in acute coronary syndrome patients in
controlled study. On the safety side, progress has been
ess notable and several unresolved issues remain. Unfor-
unately, power is not always enough, and prasugrel and
icagrelor have both raised major concerns on the safety
ront, with constant increases in major bleeding (of 22%
nd 25%, respectively) observed in the main trials (at least
or major, non-coronary artery bypass graft bleeds with
he universal TIMI deﬁnition). This detrimental effect was
ot observed in certain subgroups of patients [33] and will
robably lead to treatment algorithms according to age,
eight, clinical presentation (ST-segment elevation vs. non-
T-segment elevation myocardial infarction) and diabetic
tatus [34].
In conclusion, the future of antiplatelet therapy seems
omplex, with genetic testing, platelet function testing,
ailored therapy and new, faster and stronger antiplatelet
nhibitors, which will probably make our treatment decision
little more difﬁcult; but we now have several solutions for
reating clopidogrel resistance, which hopefully should ben-
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ﬁt our coronary patients, who still bear an unacceptably
igh risk of recurrent events.
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